Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23580162 | 0.75 | PLAU (0.40) | PLAUHTTKMT2ASMN1; SMN2 | |
| SCHEMBL14919923 | 0.74 | PLAU (0.36) | PLAUHTTKMT2A | |
| SCHEMBL16000809 | 0.74 | PLAU (0.36) | PLAUHTTKMT2AMAPTALDH1A1 | |
| SCHEMBL16000810 | 0.74 | PLAU (0.39) | PLAUHTTKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL14919971 | 0.74 | PLAU (0.39) | PLAUHTTKMT2A | |
| SCHEMBL18249711 | 0.74 | ERN1 (0.37) | HTTKMT2ALMNA | |
| SCHEMBL14920534 | 0.71 | PLAU (0.44) | PLAUHTTKMT2AMAPTNPC1 | |
| SCHEMBL23580623 | 0.71 | PLAU (0.31) | PLAU | |
| SCHEMBL16828388 | 0.69 | PLAU (0.35) | PLAUS1PR1S1PR3 | |
| SCHEMBL16858482 | 0.68 | SCN9A (0.42) | PLAUSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024109919-A1 | PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 盛睿泽华医药科技（苏州）有限公司 | 2024-05-30 | — | — | WO | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | MALT1, FKBP1B, FKBP1A | PLAU 3816/4885HTT 3725/4885KMT2A 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.